This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Why Is Integra (IART) Up 10.2% Since Last Earnings Report?
by Zacks Equity Research
Integra (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Integra's (IART) Q3 Earnings Miss Estimates, 2023 View Cut
by Zacks Equity Research
The impact of lost revenues and an increase in the return provision related to the Boston product recall dent Integra's (IART) Q3 revenues.
Integra (IART) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Integra (IART) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Integra LifeSciences (IART) Q3 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Integra (IART) delivered earnings and revenue surprises of -2.56% and 1.35%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
IART vs. IDXX: Which Stock Is the Better Value Option?
by Zacks Equity Research
IART vs. IDXX: Which Stock Is the Better Value Option?
Here's Why Investors Should Retain Integra (IART) Stock Now
by Zacks Equity Research
International expansion and the strong prospects of the CSS segment bode well for Integra (IART).
Here's Why You Should Retain Integra (IART) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Integra (IART) based on the prospects of its CSS segment and a stable liquidity position.
Why Is Integra (IART) Down 7.9% Since Last Earnings Report?
by Zacks Equity Research
Integra (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Integra (IART) CSS Sales Aid, Boston Recall Hurts Growth
by Zacks Equity Research
In spite of facing foreign exchange fluctuations across its non-U.S. business, Integra (IART) is successfully broadening its international footprint.
Integra's (IART) Q2 Earnings Top Estimates, 2023 View Cut
by Zacks Equity Research
In CSS, Integra (IART) registers strong growth owing to high single-digit growth in Advanced Energy and mid-single-digit growth in CSF management during Q2.
Integra (IART) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Integra (IART) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Integra LifeSciences (IART) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Integra (IART) delivered earnings and revenue surprises of 24.56% and 1.96%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Medical Device Stocks' Q2 Earnings on Jul 27: BSX, LH & IART
by Urmimala Biswas
Medical Device companies' second-quarter results are likely to reflect a year-over-year decline. Let's see how BSX, LH and IART fare this time.
OrthoPediatrics (KIDS) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
OrthoPediatrics (KIDS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Integra LifeSciences (IART) Q2 Earnings Expected to Decline
by Zacks Equity Research
Integra (IART) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Integra's (IART) Codman EVD Catheter Study Data Favorable
by Zacks Equity Research
Integra's (IART) Codman Bactiseal EVD lowers financial burdens and guarantees a safe clinical outcome in patients with aSAH-related hydrocephalus.
Integra (IART) Completes Enrollment in the DuraSorb IDE Study
by Zacks Equity Research
Integra (IART) announces the completion of patient enrollment in the DuraSorb IDE clinical study.
New Strong Sell Stocks for June 29th
by Zacks Equity Research
NGVT, IART and BRDG have been added to the Zacks Rank #5 (Strong Sell) List on June 29, 2023.
Here's Why You Should Retain Integra (IART) Stock Now
by Zacks Equity Research
Investors continue to be optimistic about Integra Lifesciences (IART) based on the prospect of its CSS segment and ample liquidity to support M&A strategies.
Integra (IART) Builds Advanced R&D Facility in New Jersey
by Zacks Equity Research
Integra (IART) opens the Dr. Richard E. Caruso Center of Innovation and Learning in New Jersey.
Integra's (IART) Q1 Earnings Match Estimates, Margins Contract
by Zacks Equity Research
In CSS, Integra (IART) witnesses a good start to the year with double-digit growth in the CUSA product line and programmable valves as well as strong performance in instrument sales.
Integra (IART) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
Although the revenue and EPS for Integra (IART) give a sense of how its business performed in the quarter ended March 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Integra LifeSciences (IART) Q1 Earnings Meet Estimates
by Zacks Equity Research
Integra (IART) delivered earnings and revenue surprises of 0% and 2%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Integra Lifesciences (IART) Q4 Earnings Top, Revenues Drop Y/Y
by Zacks Equity Research
Integra LifeSciences (IART) delivers strong earnings growth in the fourth quarter amid challenging macro environment issues.
Integra LifeSciences (IART) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Integra (IART) delivered earnings and revenue surprises of 1.08% and 0.05%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?